Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

John A. Chabot, MD

Dr. Chabot
New York, NY

Dr. John A. Chabot

Chief, Division of GI/Endocrine Surgery & Executive Director, Pancreas Center

Herbert Irving Comprehensive Cancer Center

161 Ft. Washington Avenue, Suite: 819
New York, NY 10032

Need Help Contacting This Doctor?

With nearly three decades of medical experience, Dr. John A. Chabot is an expert in the surgical treatment of pancreatic cancer and peritoneal mesothelioma. Upon completion of his residency in 1991, Dr. Chabot signed on as surgical chief of the thyroid clinic at NewYork-Presbyterian and assistant professor of surgery at Columbia University. He has remained at the hospital, in increasingly senior positions, ever since. Throughout the years, Dr. Chabot has remained satisfied and challenged at NewYork-Presbyterian because of the hospital’s depth of expertise and its culture of innovation. Dr. Chabot has researched and published numerous articles and abstracts on the surgical treatment of pancreatic, parathyroid, thyroid and liver disease, as well as peritoneal mesothelioma.

Main Specialty: General Surgery

Other Interests & Specialties: Cancer care, pancreatic disease, cysts, surgery, tumor and cancer, mesothelioma, thyroid cancer, liver cancer, hepatobiliary pancreas disease, pancreas and biliary tract surgery, gastrointestinal cancer, liver resection surgery, sarcoma, pancreatitis laparoscopic cholecystectomy and jaundice.

Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, named one of New York Magazine's Top Doctors, Jerry Gliklich Practitioner of the Year Award, Teaching Award in Surgery for Excellence in Teaching and Mentoring

Education & Experience:

Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology. April 2016; 68(5): 729-737. doi: 10.1111/his.12807

Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy. Annals of Surgical Oncology. December 2013: 20(3): 553-559. doi: 10.1245/s10434-013-2976-8

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. European Journal of Surgical Oncology. October 2010; 36 (10): 997-1003. doi: 10.1016/j.ejso.2010.07.001

Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma. American Journal of Clinical Oncology. February 2008; 31(1): 49-54. doi: 10.1097/COC.0b013e3180684181

P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma. Clinical Cancer Research. May 2005; 11(9): 3303-3308. doi: 10.1158/1078-0432.CCR-04-1884

Treatment of Primary Peritoneal Mesothelioma by Hyperthemic Intraperitoneal Chemotherapy. Perfusion. March 1999;14(2):141-5. doi: 10.1177/026765919901400208

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To:

Legal Rights Information Guide Free Guide Request Free Guide Free Mesothelioma Guide Free 2019 Mesothelioma Guide